Upcoming Workshops
For All Cancers
For Breast Cancer
- Part II of New Trends in ImmunotherapyRegister
For Gastrointestinal Stromal Tumors
For Head and Neck Cancer
For Kidney Cancer
For Leukemia
For Melanoma
For Mesothelioma
For Multiple Myeloma
- Part I of Living with Multiple MyelomaRegister
For Prostate Cancer
For Skin Cancer
Past workshops
For All Cancers
- Understanding Diagnostic Technologies and Biomarkers
- Chemotherapy Treatment Side Effects: Prevention & Management
- Diverse Populations Participating in Decisions about Your Care with Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
- Clinical Trials: How They Transform the Treatment of Cancer
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips & Strategies to Find the Best Cancer Treatment & Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
- CAR T-Cell Therapy: What's New
- Preventing, Managing & Treating Infection in Adults Living with Cancer
- What’s New in Precision Medicine
- How Health Care Disparities May Influence Your Cancer Treatment & Care
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Taking Your Pills on Schedule: Why It Is So Important in Managing Cancer
- Emerging Importance of Telemedicine/Telehealth Appointments in Communicating with Your Health Care Team
- Cancer and Flu Shots
- Treatment Adherence: Taking Your Pills on Schedule – Why It Is So Important
- What are Biosimilars? Understanding Their Role in Cancer Treatment: Current and Future Perspectives
- Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
- Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
- Participating in Decisions about Your CarePart IV of Life with Cancer: A Guide to Getting the Best Care
- Cancer and The Workplace: Understanding Your Legal ProtectionsPart III of Life with Cancer: A Guide to Getting the Best Care
- Understanding the Costs of Care and Your Health Care CoveragePart II of Life with Cancer: A Guide to Getting the Best Care
- Trends in Oncology and Treatment Planning: What You Need to KnowPart I of Life with Cancer: A Guide to Getting the Best Care
- Taking Your Treatment on Schedule: Its Importance in Managing Cancer
- Care for Your Bones During & After Cancer Treatment: Tips to Improve Bone Health
- Participating in Decisions about Your CarePart V of Life with Cancer: A Guide to Getting the Best Care
- Medical Emergencies in Cancer Treatment
For Acute Lymphoblastic Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Treatment Update for Adults Living with Acute Lymphocytic Leukemia (ALL)
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
For Acute Myeloid Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Acute Myeloid Leukemia (AML): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Update on the Treatment of Acute Myelogenous Leukemia (AML)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Living with Acute Myelogenous Leukemia (AML)
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Updates in the Treatment of Acute Myelogenous Leukemia
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
For Basal Cell Cancer
For Bladder Cancer
- Bladder Cancer: Treatment Updates
- Bladder Cancer: Treatment UpdatePart I of Life with Bladder Cancer
- Bladder Cancer: Treatment UpdatesPart I of Life with Bladder Cancer
- Update on the Treatment of Bladder CancerPart I of Living with Bladder Cancer
- What’s New in the Treatment of Bladder CancerPart I of Life with Bladder Cancer
- Updates on the Treatment of Bladder Cancer
For Bone Cancer
For Brain Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Glioblastoma in Adults: Treatment Updates
- Update on Glioblastoma in Adults
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
- Update on Glioblastoma in Adults
For Breast Cancer
- Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- The Benefits of Clinical Trials for Triple Negative Breast Cancer
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- Metastatic Breast Cancer in African Americans: New Treatments
- Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Triple Negative Breast Cancer and African American Women
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- The Latest Developments Reported from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
- Triple Negative Breast Cancer and African American Women
- What’s New in the Treatment of Breast Cancer for Women of All Ages
- What’s New in the Treatment of Metastatic Breast Cancer
For Cervical Cancer
For Chronic Lymphocytic Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Part II of Life with Chronic Lymphocytic Leukemia (CLL)
- Update on Chronic Lymphocytic LeukemiaPart I of Life with Chronic Lymphocytic Leukemia (CLL)
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)
For Chronic Myelogenous Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Living with Chronic Myelogenous Leukemia (CML)
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
For Colorectal Cancer
- Advances in the Treatment of Colorectal Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Colorectal Cancer Treatment: Progress and Advances
- Colorectal Cancer Treatment: Progress & Advances
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Advances in the Treatment of Colorectal Cancer
- Progress in the Treatment of Colorectal Cancer
For Cutaneous T-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Update on Diffuse Large B-Cell Lymphoma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Endometrial Cancer
For Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Follicular Lymphoma: Treatment Progress
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Gastric Cancer
For Gastrointestinal Stromal Tumors
For Glioblastoma
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Glioblastoma in Adults: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Update on Glioblastoma in Adults
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
- Update on Glioblastoma in Adults
For Head and Neck Cancer
- Oral, Head & Neck Cancer: Treatment Update
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Treatment Update in Oral and Head and Neck Cancer
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
- What’s New in the Treatment of Oral and Head and Neck Cancer
For Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- What’s New in the Treatment of Hodgkin Lymphoma
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Kidney Cancer
For Leukemia
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Acute Myeloid Leukemia (AML): Treatment Updates
- Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Update on the Treatment of Acute Myelogenous Leukemia (AML)
- Update on CAR T-Cell Therapies
- Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Living with Acute Myelogenous Leukemia (AML)
- Progress in the Treatment of Myelodysplastic Syndrome (MDS)
- Living with Chronic Myelogenous Leukemia (CML)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Current Perspectives on the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Part II of Life with Chronic Lymphocytic Leukemia (CLL)
- Update on Chronic Lymphocytic LeukemiaPart I of Life with Chronic Lymphocytic Leukemia (CLL)
- Taking Your Blood Cancer Treatment on Schedule
- Updates in the Treatment of Acute Myelogenous Leukemia
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Treatment Update for Adults Living with Acute Lymphocytic Leukemia (ALL)
- Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)
- New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
For Liver Cancer
For Lung Cancer
- Non-Small Cell Lung Cancer: Biomarker Testing & Treatment TrendsPart II of Living with Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: What's NewPart I of Living with Non-Small Cell Lung Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung CancerPart III of Living with Non-Small Cell Lung Cancer
- Small Cell Lung Cancer: Treatment UpdatePart I of Living with Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: Treatment AdvancesPart I of Living with Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer: What’s NewPart I of Living with Non-Small Cell Lung Cancer
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Diverse Populations Living with Non-Small Cell Lung Cancer
- Advances in the Treatment of Lung CancerPart I of Living with Lung Cancer
- Update on Small Cell Lung Cancer Treatments
- For Caregivers: Practical Tips for Coping with Your Loved One’s Lung CancerPart II of Living with Lung Cancer
- Progress in the Treatment of Lung CancerPart I of Living with Lung Cancer
- Advances in the Treatment of Lung CancerPart I of Life with Lung Cancer
- For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the HolidaysPart II of Life with Lung Cancer
- Progress in the Treatment of Lung CancerPart I of Life with Lung Cancer
For Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma: Treatment Progress
- Diffuse Large B-Cell Lymphoma (DLBCL) Updates
- Marginal Zone Lymphoma (MZL): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Update on Marginal Zone Lymphoma (MZL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- What’s New in the Treatment of Hodgkin Lymphoma
- Treatment Update on Mantle Cell Lymphoma (MCL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Taking Your Blood Cancer Treatment on Schedule
- The Latest News in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Update on Diffuse Large B-Cell Lymphoma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Mantle Cell Lymphoma
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Treatment Update on Mantle Cell Lymphoma (MCL)
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Marginal Zone Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Marginal Zone Lymphoma (MZL): Treatment Updates
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Update on Marginal Zone Lymphoma (MZL)
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Melanoma
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- People of Color Living with Skin Cancer
- Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
- New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell CancersPart I of Living with Advanced Skin Cancer and Melanoma
- Emerging Treatments for Metastatic MelanomaPart II of Life with Advanced Skin Cancer
For Merkel Cell Carcinoma
For Mesothelioma
For Metastatic Breast Cancer
- Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
- Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
- Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
- Metastatic Breast Cancer: Treatment Updates
- HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
- The Role of Radiation Therapy in the Treatment of Breast Cancer
- Metastatic Breast Cancer in African Americans: New Treatments
- Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
- HER2-Positive Metastatic Breast Cancer: New Therapies
- Metastatic Breast Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- The Latest Developments Reported from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
- Updates from the San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
- Triple Negative Breast Cancer and African American Women
- What’s New in the Treatment of Breast Cancer for Women of All Ages
- What’s New in the Treatment of Metastatic Breast Cancer
For Multiple Myeloma
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Multiple Myeloma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Coping with the Stresses of Caregiving When Your Loved One Has Multiple MyelomaPart II of Living with Multiple Myeloma
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Multiple Myeloma
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Multiple MyelomaPart I of Life with Multiple Myeloma
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
For Myelodysplastic Syndromes
- Progress in the Treatment of Myelodysplastic Syndromes (MDS)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Myelodysplastic Syndrome (MDS)
- Taking Your Blood Cancer Treatment on Schedule
For Myelofibrosis
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
For Myeloproliferative Neoplasms
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Chronic Lymphocytic Leukemia (CLL): Treatment Updates
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Myelofibrosis
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
For Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Transplantation as a Treatment Option for Blood Cancers
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Progress in the Treatment of Follicular Lymphoma
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Ovarian Cancer
- Ovarian Cancer: Treatment Updates
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
- Ovarian Cancer: Treatment Updates
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
- Medical Update on Ovarian Cancer
- Highlights from the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting: Unite and Conquer: Accelerating Progress TogetherPart I of Your Guide to the Latest Cancer Research and Treatment
For Pancreatic Cancer
- Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
- Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
- Treatment Update on Pancreatic Cancer
For Peripheral T-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
- Update from the 2022 American Society of Hematology (ASH) Annual Meeting
- Update On Marginal Zone Lymphoma (MZL)
- Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Update from the 2021 American Society of Hematology (ASH) Annual Meeting
- Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on Diffuse Large B-Cell Lymphoma (DLBCL)
- Update on CAR T-Cell Therapies
- Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
- Update on CAR-T Cell Therapy
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- The Emerging Role of Immunotherapy in the Treatment of Lymphoma
For Polycythemia Vera
- What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
- Transplantation as a Treatment Option for Blood Cancers
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Update on CAR T-Cell Therapies
- Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
- Updates from the 2020 American Society of Hematology (ASH) Annual Meeting
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
- Taking Your Blood Cancer Treatment on Schedule
- Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches